Lite Strategy, Inc. (LITS)
1.11
+0.05
(+4.72%)
USD |
NASDAQ |
Sep 11, 16:00
1.10
-0.01
(-0.90%)
After-Hours: 20:00
Lite Strategy Enterprise Value : 31.48M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 31.48M |
| September 10, 2026 | 29.72M |
| September 09, 2026 | 29.72M |
| September 08, 2026 | 31.13M |
| September 04, 2026 | 32.53M |
| September 03, 2026 | 29.02M |
| September 02, 2026 | 29.02M |
| September 01, 2026 | 27.40M |
| August 31, 2026 | 27.10M |
| August 28, 2026 | 26.92M |
| August 27, 2026 | 27.61M |
| August 26, 2026 | 27.37M |
| August 25, 2026 | 29.37M |
| August 24, 2026 | 28.67M |
| August 21, 2026 | 27.25M |
| August 20, 2026 | 25.62M |
| August 19, 2026 | 25.50M |
| August 18, 2026 | 23.46M |
| August 17, 2026 | 23.40M |
| August 14, 2026 | 23.62M |
| August 13, 2026 | 23.94M |
| August 12, 2026 | 24.85M |
| August 11, 2026 | 24.14M |
| August 10, 2026 | 23.05M |
| August 07, 2026 | 24.36M |
| Date | Value |
|---|---|
| August 06, 2026 | 25.12M |
| August 05, 2026 | 26.04M |
| August 04, 2026 | 25.65M |
| August 03, 2026 | 26.95M |
| July 31, 2026 | 26.33M |
| July 30, 2026 | 27.16M |
| July 29, 2026 | 25.90M |
| July 28, 2026 | 26.56M |
| July 27, 2026 | 26.79M |
| July 24, 2026 | 27.20M |
| July 23, 2026 | 27.32M |
| July 22, 2026 | 28.67M |
| July 21, 2026 | 27.61M |
| July 20, 2026 | 28.67M |
| July 17, 2026 | 27.14M |
| July 16, 2026 | 26.56M |
| July 15, 2026 | 27.23M |
| July 14, 2026 | 27.50M |
| July 13, 2026 | 25.71M |
| July 10, 2026 | 27.96M |
| July 09, 2026 | 27.37M |
| July 08, 2026 | 26.80M |
| July 07, 2026 | 26.60M |
| July 06, 2026 | 26.76M |
| July 02, 2026 | 25.87M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| SELLAS Life Sciences Group, Inc. | 2.193B |
| ACADIA Pharmaceuticals, Inc. | 3.908B |
| Alnylam Pharmaceuticals, Inc. | 32.94B |
| Anika Therapeutics, Inc. | 266.01M |
| Savara, Inc. | 945.99M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -23.69M |
| Total Expenses (Quarterly) | 23.69M |
| EPS Diluted (Quarterly) | -0.6635 |
| Earnings Yield | -181.5% |
| Normalized Earnings Yield | -96.45 |